United States Transcatheter Mitral and Tricuspid Valve Device Market Snapshot
The US heart valve device market continues to be driven by the introduction of novel products and key approvals for new indications of existing products. In particular, recent approvals of transcatheter tricuspid and mitral therapies, as well as the indication expansion of TAVI devices to treat asymptomatic, severe aortic stenosis patients, will support the market in coming years.
Read our Market Snapshot to access comprehensive data and analysis on the state of the market for heart valve devices in the US from 2019 through 2034.
